Mobile

A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally adminis...

Update Il y a 4 ans
Reference: EUCTR2007-006693-28

A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with Sitagliptin as a reference arm

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this dose-ranging study is to evaluate the effects of JNJ-28431754 as compared with placebo on the change in hemoglobin A1c (A1C) from baseline to Week 12 in subjects with T2DM.

Inclusion criteria

  • Patients with Type 2 Diabetes Mellitus (T2DM)

Links